Program
Program
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tema Oncology ETF (NQ: CANC )

28.57 +0.43 (+1.53%)
Official Closing Price Updated: 4:15 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tema Oncology ETF

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
Two dominant investing themes over the past year have been AI and weight-loss drugs. 
Via Talk Markets
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will it be a Boost For Pharma Stocks Too?
Via Benzinga
EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads
Tema ETFs is redefining thematic investing, focusing on long-term structural trends & precision in security selection rather than chasing short-term fads. 
Via Benzinga
Topics ETFs
Active ETFs Appear Booming In 2023 — Tema ETFs Are Taking Them Into A New Direction
The rapid emergence of the ETF industry, marked by its AuM growth from $1 trillion to $10 trillion this past decade, was driven by passive indexed funds which thrived in a low-rates, low-volatility... 
Via Benzinga
Topics ETFs
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes,... 
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.